Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial

Table 2

Variables of the study from day 1 compared to day 7 according to the study group.

	Group A, n = 28	Group B, n = 30	Group C, n = 30
Serum pH day 1	7.38 ± 0.08	7.35 ± 0.07	7.32 ± 0.1	0.10
Serum pH day 7	7.39 ± 0.06	7.38 ± 0.05	7.40 ± 0.07	0.67
value	1.0	0.01	0.23
Serum HCO^3− (mEq/L) day 1	21.1 ± 5.4	21.3 ± 5.0	21 ± 4.5	0.96
Serum HCO^3− (mEq/L) day 7	23.2 ± 4.5	21.9 ± 4.1	24.8 ± 4.8	0.20
value	0.18	0.30	0.08
Serum K (mEq/L) day 1	4.1 ± 0.9	4.4 ± 1.2	4.3 ± 1.5	0.79
Serum K (mEq/L) day 7	3.6 ± 0.6	3.6 ± 0.6	3.7 ± 0.6	0.87
value	0.14	0.01	0.13
Serum Na (mEq/L) day 1	137 ± 7.2	135 ± 9.1	131 ± 25.9	0.39
Serum Na (mEq/L) day 7	133 ± 5.5	135 ± 7.1	138 ± 5.7	0.07
value	0.11	0.89	0.42
Serum Ca (mEq/L) day 1	9.7 ± 7.2	7.6 ± 9.1	7.9 ± 25.9	0.40
Serum Ca (mEq/L) day 7	7.6 ± 0.7	7.6 ± 1.0	7.7 ± 1.3	0.98
value	0.33	0.94	0.43
Serum PO4 (mg/dL) day 1	4.0 ± 1.4	4.4 ± 1.9	4.2 ± 1.4	0.67
Serum PO4 (mg/dL) day 7	3.6 ± 1.4	3.6 ± 1.6	3.6 ± 1.4	0.99
value	0.85	0.11	0.17
Blood Hgb (g/dL) day 1	10.1 ± 1.9	10.2 ± 2.1	10.2 ± 2.2	0.98
Blood Hgb (g/dL) day 7	9.7 ± 2.3	9.3 ± 2.3	10.2 ± 2.7	0.45
value	0.14	0.01	0.64
Serum uric acid (mg/dL) day 1	4.7 ± 2.3	5.7 ± 3.2	6.2 ± 4.6	0.48
Serum uric acid (mg/dL) day 7	3.7 ± 1.9	6.1 ± 3.3	6.2 ± 5.9	0.14
value	0.52	0.75	0.45
Leukocytes day 1 (10^3)	13.1 ± 6.4	14.8 ± 6.0	11.8 ± 5.3	0.16
Leukocytes day 7 (10^3)	10.7 ± 5.8	12.8 ± 6.5	9.9 ± 4.8	0.21
value	0.51	0.14	0.19
Platelets day 1 (10^3)	206 ± 149	265 ± 182	279 ± 169	0.22
Platelets day 7 (10^3)	295 ± 164	266 ± 144	298 ± 147	0.71
value	0.10	0.72	0.06